A phase II study of FOLFOXIRI plus bevacizumab (Bmab) as initial chemotherapy for patients (pts) with untreated metastatic colorectal cancer (mCRC): TRICC1414 (Be TRI)

被引：0

作者：

Yamada, Takeshi

Nishina, Tomohiro

Nasu, Junichiro

Matsumoto, Toshihiko

Yuasa, Yasuhiro

Shiraishi, Takeshi

Nagano, Hiroaki

Moriyama, Ichiro

Fujiwara, Toshiyoshi

Miguchi, Masashi

Yoshida, Ryosuke

Nosaka, Kimiyasu

Tanioka, Hiroaki

Nagasaka, Takeshi

Kurisu, Yasuro

Kobayashi, Michiya

Tsuchihashi, Kenji

Inukai, Michio

Kikuchi, Takashi

Shinozaki, Katsunori

机构：

[1] Univ Tsukuba, Fac Med, Div Gastroenterol, Tsukuba, Ibaraki, Japan

[2] Natl Hosp Org Shikoku Canc Ctr, Matsuyama, Ehime, Japan

[3] Okayama Saiseikai Gen Hosp, Dept Internal Med, Okayama, Japan

[4] Himeji Red Cross Hosp, Himeji, Hyogo, Japan

[5] Tokushima Red Cross Hosp, Tokushima, Japan

[6] Matsuyama Red Cross Hosp, Dept Med Oncol, Matsuyama, Ehime, Japan

[7] Yamaguchi Univ, Grad Sch Med, Dept Gastroenterol Sugery, Ube, Yamaguchi, Japan

[8] Shimane Univ Hosp, Izumo, Shimane, Japan

[9] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Gastroenterol Surg, Okayama, Japan

[10] Hiroshima City Asa Citizens Hosp, Dept Surg, Hiroshima, Japan

[11] Okayama Rosai Hosp, Dept Surg, Okayama, Japan

[12] Sanin Rosai Hosp, Dept Surg, Yonego, Japan

[13] Kawasaki Med Sch Hosp, Dept Clin Oncol, Kurashiki, Okayama, Japan

[14] Hamada Med Ctr, Dept Surg, Hamada, Japan

[15] Kochi Med Sch, Nankoku, Kochi, Japan

[16] Kyushu Univ Hosp, Dept Hematol Oncol & Cardiovasc Med, Fukuoka, Japan

[17] Okayama Saiseikai Gen Hosp, Okayama, Japan

[18] Fdn Biomed Res & Innovat Kobe Med Innovat, Kobe, Hyogo, Japan

[19] Hiroshima Prefectural Hosp, Hiroshima, Japan

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 04期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

134

引用

页数：2

共 50 条

[1] A phase II study of FOLFOXIRI plus bevacizumab as initial chemotherapy for patients with untreated metastatic colorectal cancer: TRICC1414 (BeTRI)
Shinozaki, Katsunori
Yamada, Takeshi
Nasu, Junichiro
Matsumoto, Toshihiko
Yuasa, Yasuhiro
Shiraishi, Takeshi
Nagano, Hiroaki
Moriyama, Ichiro
Fujiwara, Toshiyoshi
Miguchi, Masashi
Yoshida, Ryosuke
Nozaka, Kimiyasu
Tanioka, Hiroaki
Nagasaka, Takeshi
Kurisu, Yasuro
Kobayashi, Michiya
Tsuchihashi, Kenji
Inukai, Michio
Kikuchi, Takashi
Nishina, Tomohiro
[J]. INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2021, 26 (02) : 399 - 408
[2] A phase II study of FOLFOXIRI plus bevacizumab as initial chemotherapy for patients with untreated metastatic colorectal cancer: TRICC1414 (BeTRI)
Katsunori Shinozaki
Takeshi Yamada
Junichiro Nasu
Toshihiko Matsumoto
Yasuhiro Yuasa
Takeshi Shiraishi
Hiroaki Nagano
Ichiro Moriyama
Toshiyoshi Fujiwara
Masashi Miguchi
Ryosuke Yoshida
Kimiyasu Nozaka
Hiroaki Tanioka
Takeshi Nagasaka
Yasuro Kurisu
Michiya Kobayashi
Kenji Tsuchihashi
Michio Inukai
Takashi Kikuchi
Tomohiro Nishina
[J]. International Journal of Clinical Oncology, 2021, 26 : 399 - 408
[3] FOLFOXIRI plus bevacizumab (BEV) in patients (pts) with previously untreated metastatic colorectal cancer (mCRC): Preliminary safety results from the OPAL study
Stein, Alexander
Atanackovic, Djordje
Hildebrandt, Bert
Stuebs, Patrick
Steffens, Claus-Christoph
Brugger, Wolfram
Hapke, Gunnar
Illerhaus, Gerald
Bluemner, Ernst
Bokemeyer, Carsten
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
[4] A PHASE II STUDY OF CAPECITABINE, IRINOTECAN, AND BEVACIZUMAB (XELIRI-A) IN PATIENTS (PTS) WITH PREVIOUSLY UNTREATED METASTATIC COLORECTAL CANCER (MCRC)
Chen, E.
Welch, S.
Kryzanowska, M.
Mackay, H.
Knox, J.
Feld, R.
Petronis, J.
Blatter, C.
Wang, L.
Moore, M.
[J]. ANNALS OF ONCOLOGY, 2009, 20 : 36 - 37
[5] A phase II study of capecitabine, irinotecan, and bevacizumab (XELIRI-A) in patients (pts) with previously untreated metastatic colorectal cancer (mCRC)
Chen, E. X.
Welch, S.
Krzyzanowska, M.
MacKay, H.
Knox, J.
Feld, R.
Petronis, J.
Blatter, C.
Wang, L.
Moore, M. J.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[6] FOLFOXIRI plus bevacizumab (BEV) in patients (pts) with previously untreated metastatic colorectal cancer (mCRC): Final survival and pharmacogenomic profiling results from the OPAL study
Bokemeyer, C.
Atanackovic, D.
Stoehlmacher, J.
Hildebrandt, B.
Stuebs, P.
Steffens, C.
Brugger, W.
Hapke, G.
Illerhaus, G.
Bluemner, E.
Stein, A.
[J]. ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 100 - 100
[7] KRAS and BRAF mutational analyses in a phase II trial of first-line FOLFOXIRI plus bevacizumab (BV) in metastatic colorectal cancer (mCRC) patients (pts)
Salvatore, L.
Loupakis, F.
Fontanini, G.
Cremolini, C.
Stasi, I.
Fabbri, A.
Ciarlo, A.
Granetto, C.
Basolo, F.
Falcone, A.
[J]. EJC SUPPLEMENTS, 2009, 7 (02): : 339 - 339
[8] KRAS AND BRAF MUTATIONAL ANALYSES IN A PHASE II TRIAL OF FIRST-LINE FOLFOXIRI PLUS BEVACIZUMAB (BV) IN METASTATIC COLORECTAL CANCER (MCRC) PATIENTS (PTS)
Salvatore, L.
Loupakis, F.
Cremolini, C.
Lupi, C.
Masi, G.
Sensi, E.
Stasi, I
Fornaro, L.
Vasile, E.
Schirripa, M.
Truscelli, K.
Giannini, R.
Baldi, G. G.
Altavilla, A.
Ciarlo, A.
Granetto, C.
Fea, E.
Fontanini, G.
Basolo, F.
Falcone, A.
[J]. ANNALS OF ONCOLOGY, 2009, 20
[9] A PHASE I STUDY OF AXITINIB (AG-013736) PLUS FOLFOX CHEMOTHERAPY AND BEVACIZUMAB IN PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (MCRC)
Abhyankar, V. V.
Sharma, S.
Trowbridge, R. C.
Robles, R. L.
Tarazi, J.
Kim, S.
Tortorici, M.
Hee, B.
Burgess, R. E.
[J]. ANNALS OF ONCOLOGY, 2008, 19 : 128 - 128
[10] Phase II study of FOLFOX, bevacizumab and erlotinib as initial therapy for patients with metastatic colorectal cancer (MCRC).
Meyerhardt, J. A.
Stuart, K.
Zhu, A.
Fuchs, C.
Bhargava, P.
Earle, C.
Blaszkowsky, L.
Lawrence, C.
Battu, S.
Ryan, D. P.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 157S - 157S

← 1 2 3 4 5 →